Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer

Uchimoto, Taizo; Komura, Kazumasa; Fujiwara, Yuya; Saito, Kenkichi; Tanda, Naoki; Matsunaga, Tomohisa; Ichihashi, Atsushi; Tsutsumi, Takeshi; Tsujino, Takeshi; Yoshikawa, Yuki; Nishimoto, Yudai; Takai, Tomoaki; Minami, Koichiro; Taniguchi, Kohei; Tanaka, Tomohito; Uehara, Hirofumi; Hirano, Hajime; Nomi, Hayahito; Ibuki, Naokazu; Takahara, Kiyoshi; Inamoto, Teruo; Azuma, Haruhito

doi:10.1007/s12032-019-1332-7

Cited by 20 publications

(22 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among them, systemic inflammatory response and nutritional status are 2 important contributors [ 22 ]. Evidences showed that CAR was an important inflammation-based prognostic indicator that was associated with the survival of various cancers [ 23 24 ]. In the present study, we found that CAR was an important prognostic indicator in patients with gastric cancer, which was in agreement with previous studies [ 13 14 21 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical significance and prognostic value of C-reactive protein/albumin ratio in gastric cancer

et al. 2021

Ann Surg Treat Res

View full text Add to dashboard Cite

Purpose This study was aimed to evaluate the clinical significance and prognostic value of CRP/albumin ratio (CAR) in patients with gastric cancer. Methods The data of 205 gastric cancer patients who underwent surgery was analyzed retrospectively. The association of CAR with the clinical features and prognostic value in gastric cancer was analyzed. The data of this study was combined with previous studies to further determine the prognostic value of CAR in patients with gastric cancer using a meta-analysis method. Results Cox analysis revealed that preoperative CAR was an independent prognosis indicator in patients with gastric cancer. High expression of CAR indicated a shorter survival time than in those with lower expression. CAR has a higher prognostic value in the 1-, 3-, and 5-year overall survival in patients with gastric cancer. CAR showed significant difference regarding the gastric cancer patients' age, M stage, and clinical stage. The discriminate value of CAR in M stage of gastric cancer was high (area under the curve, 0.809). A meta-analysis combining previous data and our data showed that preoperative CAR demonstrated a significant association with the overall survival of patients with gastric cancer. Conclusion This study demonstrated that preoperative CAR could serve as an important prognostic indicator in patients with gastric cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical significance and prognostic value of C-reactive protein/albumin ratio in gastric cancer

et al. 2021

Ann Surg Treat Res

View full text Add to dashboard Cite

show abstract

“…Among them, systemic inflammatory response and nutritional status are two important contributors [21] . Evidences showed that CAR was an important inflammation-based prognostic indicator that associated with various cancer survival outcomes [22,23] . In the present study, we found that CAR was an independent prognostic indicator in patients with gastric cancer, which was in agreement with previous studies [12,13,20] .…”

Section: Discussionmentioning

confidence: 99%

Clinical significance and prognostic value of C-reactive protein/albumin ratio in gastric cancer

Liang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background C-reactive protein/albumin ratio (CAR) is a novel prognostic biomarker in several malignancies. This study was aimed to evaluate the clinical significance and prognostic value of CAR in patients with gastric cancer. Methods The data of 205 gastric cancer patients who underwent surgery was retrospectively reviewed. The association with the clinical features and prognostic value of CAR in gastric cancer was analyzed. The data of this study was combined with previous studies to further determine the prognostic value of CAR in patients with gastric cancer. Results Cox analysis revealed that preoperative CAR was an independent prognosis indicator in patients with gastric cancer. High expression of CAR indicated a shorter survival time than those with lower expression. CAR has a higher prognostic value in the 1-, 3-, 5-years of overall survival in patients with gastric cancer. However, CAR has no significant difference regarding the gastric cancer patients’ age, gender and TNM stage. The discriminated value of CAR in TNM stage of gastric cancer was moderate. A meta-analysis by combining previous data and our data showed that preoperative CAR was significantly associated with the overall survival of patients with gastric cancer. Conclusions This study demonstrated that preoperative CAR was an independent prognostic indicator in the patients with gastric cancer who underwent surgery.

show abstract

“…In the last decade, several new drugs approved by FDA have emerged with improved clinical outcomes in metastatic CRPC (mCRPC) patients, including androgen signaling inhibitors (ASIs: abiraterone, enzalutamide, and apalutamide), cabazitaxel, and radium-223 [8][9][10][11][12][13]. Those new agents have innovated on the treatment strategy for mCRPC, which now raises new questions, i.e., the precise treatment sequence and uncovering a reliable marker to predict the treatment outcomes using those drugs for mCRPC patients [14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer

Uchimoto

Komura

Fukuokaya

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

The identification of early or primary resistance to androgen signaling inhibitors (ASIs) is of great value for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This study evaluates the predictive value of prostate-specific antigen (PSA) response at dour weeks of first-line ASIs treatment for mCRPC patients. A total of 254 patients treated with ASIs (abiraterone acetate: AA and enzalutamide: Enz) at the first-line treatment are retrospectively analyzed. Patients are stratified according to the achievement of >30% PSA decline at 4 and 12 weeks from the treatment initiation. At four weeks of the treatment, 157 patients (61.8%) achieved >30% PSA decline from the baseline. Thereafter, 177 patients (69.7%) achieved >30% PSA decline at 12 weeks of the treatment. A multivariate analysis exhibits >30% PSA decline at four weeks as an independent predictor for overall survival (OS). We note that 30 of 97 (30.9%) patients who did not achieve >30% PSA decline at four weeks consequently achieved >30% PSA decline at 12 weeks, and had a comparable favorable three years OS rate as the 147 patients achieving >30% PSA decline at both 4 and 12 weeks. To identify the variables that discriminate the patient survival in 97 patients without achieving >30% PSA decline at four weeks, a multivariate analysis is performed. The duration of androgen deprivation therapy before CRPC ≤ 12 months and Eastern Cooperative Oncology Group Performance Status ≥ 1 are identified as independent predictors for shorter OS for those patients. These data offer a concept of early treatment switch after four weeks of first-line ASIs when not observing >30% PSA decline at four weeks—particularly in patients with a modest effect of ADT and poor performance status.

show abstract

Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer

Cited by 20 publications

References 36 publications

Clinical significance and prognostic value of C-reactive protein/albumin ratio in gastric cancer

Clinical significance and prognostic value of C-reactive protein/albumin ratio in gastric cancer

Clinical significance and prognostic value of C-reactive protein/albumin ratio in gastric cancer

Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer

Contact Info

Product

Resources

About